FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Nature communications2019; 10(1); 353; doi: 10.1038/s41467-018-08081-1

Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.

Abstract: Mucosal melanoma is a rare and poorly characterized subtype of human melanoma. Here we perform a cross-species analysis by sequencing tumor-germline pairs from 46 primary human muscosal, 65 primary canine oral and 28 primary equine melanoma cases from mucosal sites. Analysis of these data reveals recurrently mutated driver genes shared between species such as NRAS, FAT4, PTPRJ, TP53 and PTEN, and pathogenic germline alleles of BRCA1, BRCA2 and TP53. We identify a UV mutation signature in a small number of samples, including human cases from the lip and nasal mucosa. A cross-species comparative analysis of recurrent copy number alterations identifies several candidate drivers including MDM2, B2M, KNSTRN and BUB1B. Comparison of somatic mutations in recurrences and metastases to those in the primary tumor suggests pervasive intra-tumor heterogeneity. Collectively, these studies suggest a convergence of some genetic changes in mucosal melanomas between species but also distinctly different paths to tumorigenesis.
Get Full Text
Publication Date: 2019-01-21 PubMed ID: 30664638PubMed Central: PMC6341101DOI: 10.1038/s41467-018-08081-1Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study explores the genetic make-up of a rare subtype of human melanoma called mucosal melanoma by comparing its genomic landscape with that of similar types of melanoma found in dogs and horses.

Background

  • Mucosal melanoma is a type of skin cancer that is not well understood due to its rarity.
  • This study aims to gain insights into this disease by comparing its genetic profile with similar diseases found in dogs and horses.

Method

  • To compare the genomic landscape, the research team sequenced the genes of tumor-germline pairs from 46 human, 65 canine, and 28 equine primary melanoma cases.
  • This allowed the researchers to pinpoint recurrently mutated driver genes that are common between species, as well as identify pathogenic germline alleles.

Findings

  • Commonly mutated genes included NRAS, FAT4, PTPRJ, TP53, and PTEN.
  • Pathogenic germline alleles found included those of BRCA1, BRCA2, and TP53.
  • A UV mutation signature was detected in a small subset of samples, including those from human cases on the lip and nasal mucosa.
  • In analyzing recurrent copy number alterations, several candidate driver genes, such as MDM2, B2M, KNSTRN, and BUB1B, were identified.
  • Comparison of somatic mutations in recurrences and metastases with those in primary tumors suggested that pervasive intra-tumor heterogeneity is common.

Significance

  • The findings of this study suggest that there are some genetic overlaps in mucosal melanomas across different species.
  • However, there appear to also be unique paths to tumorigenesis for each species.
  • This research enhances our understanding of mucosal melanoma, potentially opening up new pathways for targeted treatment strategies for this rare form of skin cancer.

Cite This Article

APA
Wong K, van der Weyden L, Schott CR, Foote A, Constantino-Casas F, Smith S, Dobson JM, Murchison EP, Wu H, Yeh I, Fullen DR, Joseph N, Bastian BC, Patel RM, Martincorena I, Robles-Espinoza CD, Iyer V, Kuijjer ML, Arends MJ, Brenn T, Harms PW, Wood GA, Adams DJ. (2019). Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nat Commun, 10(1), 353. https://doi.org/10.1038/s41467-018-08081-1

Publication

Nature communications
ISSN: 2041-1723
NlmUniqueID: 101528555
Country: England
Language: English
Volume: 10
Issue: 1
Pages: 353

Researcher Affiliations

Wong, Kim
  • Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
van der Weyden, Louise
  • Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Schott, Courtney R
  • Department of Pathobiology, University of Guelph, 50 Stone Road E., Guelph, ON, N1G 2W1, Canada.
Foote, Alastair
  • Rossdales Equine Hospital and Diagnostic Centre, High Street, Newmarket, Suffolk, CB8 8JS, UK.
Constantino-Casas, Fernando
  • Department of Veterinary Medicine, Cambridge Veterinary School, University of Cambridge, Cambridge, CB3 0ES, UK.
Smith, Sionagh
  • The Royal (Dick) School of Veterinary Studies and The Roslin Institute, Easter Bush Campus, Midlothian, EH25 9RG, UK.
Dobson, Jane M
  • Department of Veterinary Medicine, Cambridge Veterinary School, University of Cambridge, Cambridge, CB3 0ES, UK.
Murchison, Elizabeth P
  • Department of Veterinary Medicine, Cambridge Veterinary School, University of Cambridge, Cambridge, CB3 0ES, UK.
Wu, Hong
  • Departments of Dermatology and Pathology, University of California, San Francisco, CA, 94143, USA.
Yeh, Iwei
  • Departments of Dermatology and Pathology, University of California, San Francisco, CA, 94143, USA.
Fullen, Douglas R
  • Departments of Pathology and Dermatology, University of Michigan Medical School, 3261 Medical Science I, 1301 Catherine, Ann Arbor, MI, 48109-5602, USA.
Joseph, Nancy
  • Departments of Dermatology and Pathology, University of California, San Francisco, CA, 94143, USA.
Bastian, Boris C
  • Departments of Dermatology and Pathology, University of California, San Francisco, CA, 94143, USA.
Patel, Rajiv M
  • Departments of Pathology and Dermatology, University of Michigan Medical School, 3261 Medical Science I, 1301 Catherine, Ann Arbor, MI, 48109-5602, USA.
Martincorena, Inigo
  • Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Robles-Espinoza, Carla Daniela
  • Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
  • Laboratorio Internacional de Investigación sobre el Genoma Humano, Universidad Nacional Autónoma de México, Campus Juriquilla, Blvd Juriquilla 3001, Santiago de Querétaro, 76230, Mexico.
Iyer, Vivek
  • Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
Kuijjer, Marieke L
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, 02215, USA.
  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
  • Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, Faculty of Medicine, University of Oslo, 0349, Oslo, Norway.
Arends, Mark J
  • University of Edinburgh, Division of Pathology, Centre for Comparative Pathology, Cancer Research UK Edinburgh Centre, Institute of Genetics & Molecular Medicine, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK.
Brenn, Thomas
  • Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
  • Department of Pathology and Laboratory Medicine, Cumming School of Medicine and Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, T2L 2K8, Canada.
Harms, Paul W
  • Departments of Pathology and Dermatology, University of Michigan Medical School, 3261 Medical Science I, 1301 Catherine, Ann Arbor, MI, 48109-5602, USA.
Wood, Geoffrey A
  • Department of Pathobiology, University of Guelph, 50 Stone Road E., Guelph, ON, N1G 2W1, Canada.
Adams, David J
  • Wellcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, UK. da1@sanger.ac.uk.

MeSH Terms

  • Animals
  • BRCA1 Protein / genetics
  • BRCA1 Protein / metabolism
  • BRCA2 Protein / genetics
  • BRCA2 Protein / metabolism
  • Cadherins / genetics
  • Cadherins / metabolism
  • Carcinogenesis / genetics
  • Carcinogenesis / metabolism
  • Carcinogenesis / pathology
  • Cell Cycle Proteins / genetics
  • Cell Cycle Proteins / metabolism
  • DNA Copy Number Variations
  • Dogs
  • GTP Phosphohydrolases / genetics
  • GTP Phosphohydrolases / metabolism
  • Gene Expression Regulation, Neoplastic
  • Germ-Line Mutation
  • Horses
  • Humans
  • Melanoma / genetics
  • Melanoma / metabolism
  • Melanoma / pathology
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Microtubule-Associated Proteins / genetics
  • Microtubule-Associated Proteins / metabolism
  • Mouth Neoplasms / genetics
  • Mouth Neoplasms / metabolism
  • Mouth Neoplasms / pathology
  • Mucous Membrane / metabolism
  • Mucous Membrane / pathology
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism
  • Neoplasm Recurrence, Local
  • PTEN Phosphohydrolase / genetics
  • PTEN Phosphohydrolase / metabolism
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism
  • Proto-Oncogene Proteins c-mdm2 / genetics
  • Proto-Oncogene Proteins c-mdm2 / metabolism
  • Receptor-Like Protein Tyrosine Phosphatases, Class 3 / genetics
  • Receptor-Like Protein Tyrosine Phosphatases, Class 3 / metabolism
  • Skin Neoplasms / genetics
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / pathology
  • Species Specificity
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism
  • Tumor Suppressor Proteins / genetics
  • Tumor Suppressor Proteins / metabolism

Grant Funding

  • Wellcome Trust
  • 21717 / Cancer Research UK
  • 21777 / Cancer Research UK
  • MR/S01473X/1 / Medical Research Council

Conflict of Interest Statement

The authors declare no competing interests.

References

This article includes 70 references
  1. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine.. Genes Dev. 2012;26:1131–1155.
    doi: 10.1101/gad.191999.112pmc: PMC3371404pubmed: 22661227google scholar: lookup
  2. Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal melanoma: a literature review.. Curr. Oncol. Rep. 2018;20:28.
    doi: 10.1007/s11912-018-0675-0pubmed: 29569184google scholar: lookup
  3. McLaughlin CC. Incidence of noncutaneous melanomas in the U.S.. Cancer 2005;103:1000–1007.
    doi: 10.1002/cncr.20866pubmed: 15651058google scholar: lookup
  4. Baloglu A, Bezircioglu I, Cetinkaya B, Yavuzcan A. Primary malignant melanoma of the vagina.. Arch. Gynecol. Obstet. 2009;280:819–822.
    doi: 10.1007/s00404-009-1009-0pubmed: 19242707google scholar: lookup
  5. Zhang T, Dutton-Regester K, Brown KM, Hayward NK. The genomic landscape of cutaneous melanoma.. Pigment Cell Melanoma Res. 2016;29:266–283.
    doi: 10.1111/pcmr.12459pubmed: 26833684google scholar: lookup
  6. Hayward NK. Whole-genome landscapes of major melanoma subtypes.. Nature 2017;545:175–180.
    doi: 10.1038/nature22071pubmed: 28467829google scholar: lookup
  7. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma.. Cell 2015;161:1681–1696.
    pmc: PMC4580370pubmed: 26091043
  8. Furney SJ. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.. J. Pathol. 2013;230:261–269.
    doi: 10.1002/path.4204pubmed: 23620124google scholar: lookup
  9. Luksza M. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.. Nature 2017;551:517–520.
    pmc: PMC6137806pubmed: 29132144
  10. Schadendorf D. Melanoma.. Nat. Rev. Dis. Prim. 2015;1:15003.
    doi: 10.1038/nrdp.2015.3pubmed: 27188223google scholar: lookup
  11. Perez-Guijarro E, Day CP, Merlino G, Zaidi MR. Genetically engineered mouse models of melanoma.. Cancer 2017;123:2089–2103.
    doi: 10.1002/cncr.30684pmc: PMC5445933pubmed: 28543694google scholar: lookup
  12. Day CP, Marchalik R, Merlino G, Michael H. Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevance.. Lab. Investig. 2017;97:698–705.
    doi: 10.1038/labinvest.2016.155pmc: PMC5514606pubmed: 28092363google scholar: lookup
  13. van der Weyden L. Cross-species models of human melanoma.. J. Pathol. 2016;238:152–165.
    doi: 10.1002/path.4632pmc: PMC4832391pubmed: 26354726google scholar: lookup
  14. Barutello G. Strengths and weaknesses of pre-clinical models for human melanoma treatment: dawn of dogs’ revolution for immunotherapy.. Int. J. Mol. Sci. 2018;19:pii: E799.
    doi: 10.3390/ijms19030799pmc: PMC5877660pubmed: 29534457google scholar: lookup
  15. Hernandez B. Naturally occurring canine melanoma as a predictive comparative oncology model for human mucosal and other triple wild-type melanomas.. Int. J. Mol. Sci. 2018;19:pii: E394.
    doi: 10.3390/ijms19020394pmc: PMC5855616pubmed: 29385676google scholar: lookup
  16. Schiffman JD, Breen M. Comparative oncology: what dogs and other species can teach us about humans with cancer.. Philos. Trans. R Soc. Lond. B Biol. Sci. 2015;370:pii: 20140231.
    doi: 10.1098/rstb.2014.0231pmc: PMC4581033pubmed: 26056372google scholar: lookup
  17. Richter A. RAS gene hot-spot mutations in canine neoplasias.. J. Hered. 2005;96:764–765.
    doi: 10.1093/jhered/esi121pubmed: 16251512google scholar: lookup
  18. Cibulskis K. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.. Nat. Biotechnol. 2013;31:213–219.
    doi: 10.1038/nbt.2514pmc: PMC3833702pubmed: 23396013google scholar: lookup
  19. Wei L. MAC: identifying and correcting annotation for multi-nucleotide variations.. BMC Genom. 2015;16:569.
    doi: 10.1186/s12864-015-1779-7pmc: PMC4521406pubmed: 26231518google scholar: lookup
  20. Saunders CT. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs.. Bioinformatics 2012;28:1811–1817.
    doi: 10.1093/bioinformatics/bts271pubmed: 22581179google scholar: lookup
  21. Favero F. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.. Ann. Oncol. 2015;26:64–70.
    doi: 10.1093/annonc/mdu479pmc: PMC4269342pubmed: 25319062google scholar: lookup
  22. Alexandrov LB. Signatures of mutational processes in human cancer.. Nature 2013;500:415–421.
    doi: 10.1038/nature12477pmc: PMC3776390pubmed: 23945592google scholar: lookup
  23. Lyu J. Whole-exome sequencing of oral mucosal melanoma reveals mutational profile and therapeutic targets.. J. Pathol. 2018;244:358–366.
    doi: 10.1002/path.5017pubmed: 29230811google scholar: lookup
  24. Hintzsche JD. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.. Melanoma Res. 2017;27:189–199.
    doi: 10.1097/CMR.0000000000000345pmc: PMC5470740pubmed: 28296713google scholar: lookup
  25. Kuijjer ML, Paulson JN, Salzman P, Ding W, Quackenbush J. Cancer subtype identification using somatic mutation data.. Br. J. Cancer. 2018;118:1492–1501.
    doi: 10.1038/s41416-018-0109-7pmc: PMC5988673pubmed: 29765148google scholar: lookup
  26. Hendricks WPD. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.. PLoS Genet. 2018;14:e1007589.
    doi: 10.1371/journal.pgen.1007589pmc: PMC6126841pubmed: 30188888google scholar: lookup
  27. Lee CS. Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma.. Nat. Genet. 2014;46:1060–1062.
    doi: 10.1038/ng.3091pmc: PMC4324615pubmed: 25194279google scholar: lookup
  28. Valentine BA. Equine melanocytic tumors: a retrospective study of 53 horses (1988 to 1991).. J. Vet. Intern. Med. 1995;9:291–297.
    pubmed: 8531173
  29. He J, Mansouri A, Das S. Alpha Thalassemia/Mental Retardation Syndrome X-Linked, the alternative lengthening of telomere phenotype, and gliomagenesis: current understandings and future potential.. Front. Oncol. 2017;7:322.
    doi: 10.3389/fonc.2017.00322pmc: PMC5766634pubmed: 29359122google scholar: lookup
  30. Chudasama P. Integrative genomic and transcriptomic analysis of leiomyosarcoma.. Nat. Commun. 2018;9:144.
    doi: 10.1038/s41467-017-02602-0pmc: PMC5762758pubmed: 29321523google scholar: lookup
  31. Robles-Espinoza CD. POT1 loss-of-function variants predispose to familial melanoma.. Nat. Genet. 2014;46:478–481.
    doi: 10.1038/ng.2947pmc: PMC4266105pubmed: 24686849google scholar: lookup
  32. Horn S. TERT promoter mutations in familial and sporadic melanoma.. Science 2013;339:959–961.
    doi: 10.1126/science.1230062pubmed: 23348503google scholar: lookup
  33. Modrek AS. Low-grade astrocytoma mutations in IDH1, P53, and ATRX cooperate to block differentiation of human neural stem cells via repression of SOX2.. Cell Rep. 2017;21:1267–1280.
    doi: 10.1016/j.celrep.2017.10.009pmc: PMC5687844pubmed: 29091765google scholar: lookup
  34. Robertson AG. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma.. Cancer Cell. 2017;32:204–220.e215.
    doi: 10.1016/j.ccell.2017.07.003pmc: PMC5619925pubmed: 28810145google scholar: lookup
  35. Kusters-Vandevelde HVN. Whole-exome sequencing of a meningeal melanocytic tumour reveals activating CYSLTR2 and EIF1AX hotspot mutations and similarities to uveal melanoma.. Brain Tumor Pathol. 2018;35:127–130.
    doi: 10.1007/s10014-018-0308-1pubmed: 29476293google scholar: lookup
  36. Etemadmoghadam D. EIF1AX and NRAS mutations co-occur and cooperate in low-grade serous ovarian carcinomas.. Cancer Res. 2017;77:4268–4278.
    doi: 10.1158/0008-5472.CAN-16-2224pubmed: 28646021google scholar: lookup
  37. Nikolaev SI. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.. Nat. Genet. 2011;44:133–139.
    doi: 10.1038/ng.1026pubmed: 22197931google scholar: lookup
  38. Curtin JA. Distinct sets of genetic alterations in melanoma.. N. Engl. J. Med. 2005;353:2135–2147.
    doi: 10.1056/NEJMoa050092pubmed: 16291983google scholar: lookup
  39. Poorman K. Comparative cytogenetic characterization of primary canine melanocytic lesions using array CGH and fluorescence in situ hybridization.. Chromosome Res. 2015;23:171–186.
    doi: 10.1007/s10577-014-9444-6pmc: PMC5462112pubmed: 25511566google scholar: lookup
  40. Kraehn GM. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases.. Br. J. Cancer. 2001;84:72–79.
    doi: 10.1054/bjoc.2000.1535pmc: PMC2363612pubmed: 11139316google scholar: lookup
  41. Mermel CH. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.. Genome Biol. 2011;12:R41.
    doi: 10.1186/gb-2011-12-4-r41pmc: PMC3218867pubmed: 21527027google scholar: lookup
  42. Diskin SJ. STAC: a method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments.. Genome Res. 2006;16:1149–1158.
    doi: 10.1101/gr.5076506pmc: PMC1557772pubmed: 16899652google scholar: lookup
  43. Janikovits J. High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer.. Oncoimmunology 2018;7:e1390640.
    doi: 10.1080/2162402X.2017.1390640pmc: PMC5749658pubmed: 29308317google scholar: lookup
  44. Rio Frio T. Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia.. N. Eng. J. Med. 2010;363:2628–2637.
    doi: 10.1056/NEJMoa1006565pubmed: 21190457google scholar: lookup
  45. Ablain J. Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma.. Science 2018;362:1055–1060.
    doi: 10.1126/science.aa攉pmc: PMC6475924pubmed: 30385465google scholar: lookup
  46. Wade M, Wong ET, Tang M, Stommel JM, Wahl GM. Hdmx modulates the outcome of p53 activation in human tumor cells.. J. Biol. Chem. 2006;281:33036–33044.
    doi: 10.1074/jbc.M605405200pubmed: 16905769google scholar: lookup
  47. Kool M. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.. Cancer Cell. 2014;25:393–405.
    doi: 10.1016/j.ccr.2014.02.004pmc: PMC4493053pubmed: 24651015google scholar: lookup
  48. Vignot S. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles.. Eur. J. Cancer. 2015;51:791–799.
    doi: 10.1016/j.ejca.2015.02.012pubmed: 25797355google scholar: lookup
  49. Potrony M. Update in genetic susceptibility in melanoma.. Ann. Transl. Med. 2015;3:210.
    pmc: PMC4583600pubmed: 26488006
  50. Klein JD, Kupferman ME. Li-Fraumeni syndrome presenting as mucosal melanoma: Case report and treatment considerations.. Head Neck. 2017;39:E20–e22.
    doi: 10.1002/hed.24594pubmed: 27726232google scholar: lookup
  51. Abeliovich D. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.. Am. J. Hum. Genet. 1997;60:505–514.
    pmc: PMC1712523pubmed: 9042909
  52. Simard J. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families.. Nat. Genet. 1994;8:392–398.
    doi: 10.1038/ng1294-392pubmed: 7894492google scholar: lookup
  53. Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.. Annu. Rev. Med. 2015;66:455–470.
    doi: 10.1146/annurev-med-050913-022545pubmed: 25341009google scholar: lookup
  54. Win AK. Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH.. Int. J. Cancer. 2016;139:1557–1563.
    doi: 10.1002/ijc.30197pmc: PMC5094810pubmed: 27194394google scholar: lookup
  55. Shaag A. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.. Hum. Mol. Genet. 2005;14:555–563.
    doi: 10.1093/hmg/ddi052pubmed: 15649950google scholar: lookup
  56. Rosengren Pielberg G. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse.. Nat. Genet. 2008;40:1004–1009.
    doi: 10.1038/ng.185pubmed: 18641652google scholar: lookup
  57. Uehling DE, Harris PA. Recent progress on MAP kinase pathway inhibitors.. Bioorg. Med. Chem. Lett. 2015;25:4047–4056.
    doi: 10.1016/j.bmcl.2015.07.093pubmed: 26298497google scholar: lookup
  58. Bax MJ, Brown MD, Rothberg PG, Laughlin TS, Scott GA. Pigmented epithelioid melanocytoma (animal-type melanoma): an institutional experience.. J. Am. Acad. Dermatol. 2017;77:328–332.
    doi: 10.1016/j.jaad.2017.01.029pubmed: 28416343google scholar: lookup
  59. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.. arXiv 2013;1303.
  60. McKenna A. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.. Genome Res. 2010;20:1297–1303.
    doi: 10.1101/gr.107524.110pmc: PMC2928508pubmed: 20644199google scholar: lookup
  61. McLaren W. The Ensembl Variant Effect Predictor.. Genome Biol. 2016;17:122.
    doi: 10.1186/s13059-016-0974-4pmc: PMC4893825pubmed: 27268795google scholar: lookup
  62. Lek M. Analysis of protein-coding genetic variation in 60,706 humans.. Nature 2016;536:285–291.
    doi: 10.1038/nature19057pmc: PMC5018207pubmed: 27535533google scholar: lookup
  63. Bai B. DoGSD: the dog and wolf genome SNP database.. Nucleic Acids Res. 2015;43:D777–D783.
    doi: 10.1093/nar/gkᅴpmc: PMC4383968pubmed: 25404132google scholar: lookup
  64. Abecasis GR. A map of human genome variation from population-scale sequencing.. Nature 2010;467:1061–1073.
    doi: 10.1038/nature09534pmc: PMC3042601pubmed: 20981092google scholar: lookup
  65. Zheng X. A high-performance computing toolset for relatedness and principal component analysis of SNP data.. Bioinformatics 2012;28:3326–3328.
    doi: 10.1093/bioinformatics/bts606pmc: PMC3519454pubmed: 23060615google scholar: lookup
  66. Gehring JS, Fischer B, Lawrence M, Huber W. SomaticSignatures: inferring mutational signatures from single-nucleotide variants.. Bioinformatics 2015;31:3673–3675.
    pmc: PMC4817139pubmed: 26163694
  67. Alexandrov LB. Clock-like mutational processes in human somatic cells.. Nat. Genet. 2015;47:1402–1407.
    doi: 10.1038/ng.3441pmc: PMC4783858pubmed: 26551669google scholar: lookup
  68. Herrero J.. Ensembl comparative genomics resources.. Database 2016.
    pmc: PMC4761110pubmed: 26896847
  69. Futreal PA. A census of human cancer genes.. Nat. Rev. Cancer. 2004;4:177–183.
    doi: 10.1038/nrc1299pmc: PMC2665285pubmed: 14993899google scholar: lookup
  70. Rieder S, Taourit S, Mariat D, Langlois B, Guerin G. Mutations in the agouti (ASIP), the extension (MC1R), and the brown (TYRP1) loci and their association to coat color phenotypes in horses (Equus caballus). Mamm. Genome. 2001;12:450–455.
    doi: 10.1007/s003350020017pubmed: 11353392google scholar: lookup

Citations

This article has been cited 84 times.
  1. Basurto-Lozada P, Vázquez-Cruz ME, Molina-Aguilar C, Jiang A, Deacon DC, Cerrato-Izaguirre D, Simonin-Wilmer I, Arriaga-González FG, Contreras-Ramírez KL, Ferro-Rodríguez E, Billington J, Dawson ET, Wong-Ramirez JRC, Ramos-Galguera JI, Álvarez-Cano A, García-Ortega DY, García-Salinas OI, Hidalgo-Miranda A, Cisneros-Villanueva M, Johansson PA, Martínez-Said H, Gallego-García P, Arends MJ, Ferreira I, Tullett M, Olvera-León R, van der Weyden L, Del Castillo Velasco-Herrera M, Roldán-Marín R, Vidaurri de la Cruz H, Tavares-de-la-Paz LA, Hinojosa-Ugarte D, Belote RL, Bishop DT, Díaz-Gay M, Alexandrov LB, Sánchez-Pérez Y, In GK, White RM, Possik PA, Judson-Torres RL, Adams DJ, Robles-Espinoza CD. Ancestry and somatic profile indicate acral melanoma origin and prognosis. Nature 2026 Mar;651(8104):221-230.
    doi: 10.1038/s41586-025-09967-zpubmed: 41708869google scholar: lookup
  2. Ferreira WAS, de Sousa AGCN, Faro TAS, de Oliveira EHC. Transcriptomic profiling of a canine malignant eyelid melanoma. Braz J Vet Med 2026;48:e004025.
    doi: 10.29374/2527-2179.bjvm004025pubmed: 41395361google scholar: lookup
  3. Ostendarp C, Barton AK. Intraocular Tumors in Horses: Diagnosis, Tumor Classification, Oncologic Assessment and Therapy. Vet Sci 2025 Oct 17;12(10).
    doi: 10.3390/vetsci12101006pubmed: 41150147google scholar: lookup
  4. Tesena P, Vinijkumthorn R, Kingkaw A, Yanyongsirikarn P, Phasuk K, Ploypetch S, Phaonakrop N, Roytrakul S, Vongsangnak W, Prapaiwan N. Probing Wnt pathway and functional signal in equine melanocytic neoplasms through quantitative proteomics and immunohistochemistry. BMC Vet Res 2025 Aug 7;21(1):509.
    doi: 10.1186/s12917-025-04956-wpubmed: 40775356google scholar: lookup
  5. Wei BR, Verdi V, Zhang S, Mock BA, Shive HR, Simpson RM. Capacity for Compensatory Cyclin D2 Response Confers Trametinib Resistance in Canine Mucosal Melanoma. Cancers (Basel) 2025 Jul 15;17(14).
    doi: 10.3390/cancers17142357pubmed: 40723239google scholar: lookup
  6. Babu S, Chen J, Baron CS, Sun K, Robitschek E, McConnell AM, Wu C, Dedeilia A, Sade-Feldman M, Modhurima R, Manos MP, Chen KY, Cox AM, Ludwig CG, Kellis M, Buchbinder EI, Hacohen N, Yang J, Boland GM, Abraham BJ, Liu D, Zon LI, Insco ML. Specific oncogene activation of the cell of origin in mucosal melanoma. Nat Commun 2025 Jul 22;16(1):6750.
    doi: 10.1038/s41467-025-61937-1pubmed: 40695831google scholar: lookup
  7. Jing Y, Yuan Y, Yu Y, Zhao H, Yang H, Wang X. p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma. Discov Oncol 2025 Jul 6;16(1):1270.
    doi: 10.1007/s12672-025-03062-5pubmed: 40618312google scholar: lookup
  8. Wei BR, Verdi V, Zhang S, Mock BA, Shive HR, Simpson RM. Capacity for compensatory cyclin D2 response confers trametinib resistance in canine mucosal melanoma. bioRxiv 2025 Apr 26;.
    doi: 10.1101/2025.04.24.650512pubmed: 40568110google scholar: lookup
  9. Fanelli A, Mazzone E, Giannuzzi D, Marconato L, Aresu L. Expanding the Spectrum of Canine Diffuse Large B-Cell Lymphoma Genetic Aberrations Through Whole Genome Sequencing Analysis. Vet Comp Oncol 2025 Sep;23(3):346-357.
    doi: 10.1111/vco.13059pubmed: 40320296google scholar: lookup
  10. Blacklock KLB, Donnelly K, Lu Y, Pozo JD, Glendinning L, Polton G, Selmic L, Tanis JB, Killick D, Parys M, Morris JS, Breathnach I, Zago S, Gould SM, Shaw DJ, Tivers MS, Malucelli D, Marques A, Purzycka K, Cantatore M, Mathers ME, Stares M, Meynert A, Patton EE. Oronasal mucosal melanoma is defined by two transcriptional subtypes in humans and dogs with implications for diagnosis and therapy. J Pathol 2025 Mar;265(3):245-259.
    doi: 10.1002/path.6377pubmed: 39828982google scholar: lookup
  11. Passos Barbosa MM, Kamerer RL, Schmit J, Lopez AJ, Uyehara R, Tighe R, Battula S, Kaufman HL, Fan TM. Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide-Tethered IL-12 in Dogs with Advanced Malignant Melanoma. Mol Cancer Ther 2025 Mar 4;24(3):406-418.
    doi: 10.1158/1535-7163.MCT-24-0317pubmed: 39632727google scholar: lookup
  12. Gualtieri P, Lee BI, Beeney A, Hart C, Leary D, Martin T, Boss MK. Response of Spontaneous Oral Tumors in Canine Cancer Patients Treated with Stereotactic Body Radiation Therapy (SBRT). Radiat Res 2024 Dec 1;202(6):807-824.
    doi: 10.1667/RADE-24-00079.1pubmed: 39478420google scholar: lookup
  13. Beebe E, Krudewig C, Motamed Z, Malbon A, Markkanen E. Stromal Expression Profiling Reveals Immune-Driven Adaption to Malignancy in Canine Melanoma Subtypes. Vet Comp Oncol 2025 Mar;23(1):20-29.
    doi: 10.1111/vco.13021pubmed: 39420530google scholar: lookup
  14. Sekar G, Bahot A, Bansode M, Phadnis A, Sarode SC, Sharma NK. Potentiation of Tumor Hallmarks by the Loss of GULO, a Vitamin C Biosynthesis Gene in Humans. Curr Mol Med 2025;25(8):991-1001.
    doi: 10.2174/0115665240328074241003110326pubmed: 39411937google scholar: lookup
  15. Dagli MLZ, Nagamine MK, Ikeda TL, da Fonseca IIM, Kremer FS, Seixas FK, Hernandez CD, Leite JVP, Yasumaru CC, Massoco CO, Hsieh R, Lourenço SV, Collares TV. Identification of mutations in canine oral mucosal melanomas by exome sequencing and comparison with human melanomas. Sci Rep 2024 Oct 15;14(1):24174.
    doi: 10.1038/s41598-024-74748-zpubmed: 39406779google scholar: lookup
  16. Lo Giudice A, Porcellato I, Giglia G, Sforna M, Lepri E, Mandara MT, Leonardi L, Mechelli L, Brachelente C. Exploring the Epidemiology of Melanocytic Tumors in Canine and Feline Populations: A Comprehensive Analysis of Diagnostic Records from a Single Pathology Institution in Italy. Vet Sci 2024 Sep 14;11(9).
    doi: 10.3390/vetsci11090435pubmed: 39330814google scholar: lookup
  17. Mazzone E, Aresu L. Comprehensive Analysis of Microsatellite Instability in Canine Cancers: Implications for Comparative Oncology and Personalized Veterinary Medicine. Animals (Basel) 2024 Aug 27;14(17).
    doi: 10.3390/ani14172484pubmed: 39272269google scholar: lookup
  18. Li S, Liu Z, Lv J, Lv D, Xu H, Shi H, Liu G, Lin D, Jin Y. Establishment of Canine Oral Mucosal Melanoma Cell Lines and Their Xenogeneic Animal Models. Cells 2024 Jun 6;13(11).
    doi: 10.3390/cells13110992pubmed: 38891124google scholar: lookup
  19. Aupperle-Lellbach H, Kehl A, de Brot S, van der Weyden L. Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future. Vet Sci 2024 May 2;11(5).
    doi: 10.3390/vetsci11050199pubmed: 38787171google scholar: lookup
  20. Babu S, Chen J, Robitschek E, Baron CS, McConnell A, Wu C, Dedeilia A, Sade-Feldman M, Modhurima R, Manos MP, Chen KY, Cox AM, Ludwig CG, Yang J, Kellis M, Buchbinder EI, Hacohen N, Boland GM, Abraham BJ, Liu D, Zon LI, Insco ML. Specific oncogene activation of the cell of origin in mucosal melanoma. bioRxiv 2024 Apr 26;.
    doi: 10.1101/2024.04.22.590595pubmed: 38712250google scholar: lookup
  21. Pimenta J, Prada J, Pires I, Cotovio M. The Impact of Excision Interval on Equine Melanoma Progression: Time Matters?. Animals (Basel) 2024 Apr 22;14(8).
    doi: 10.3390/ani14081244pubmed: 38672392google scholar: lookup
  22. Polton G, Borrego JF, Clemente-Vicario F, Clifford CA, Jagielski D, Kessler M, Kobayashi T, Lanore D, Queiroga FL, Rowe AT, Vajdovich P, Bergman PJ. Melanoma of the dog and cat: consensus and guidelines. Front Vet Sci 2024;11:1359426.
    doi: 10.3389/fvets.2024.1359426pubmed: 38645640google scholar: lookup
  23. Gao Y, Packeiser EM, Wendt S, Sekora A, Cavalleri JV, Pratscher B, Alammar M, Hühns M, Brenig B, Junghanss C, Nolte I, Murua Escobar H. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines. Genes (Basel) 2024 Feb 3;15(2).
    doi: 10.3390/genes15020202pubmed: 38397192google scholar: lookup
  24. Pimenta J, Prada J, Pires I, Cotovio M. Cyclooxygenase-2 (COX-2) Expression in Equine Melanocytic Tumors. Vet Sci 2024 Feb 7;11(2).
    doi: 10.3390/vetsci11020077pubmed: 38393095google scholar: lookup
  25. Jin L, Zhang X, Fan M, Li W, Zhang X. NamiRNA-mediated high expression of KNSTRN correlates with poor prognosis and immune infiltration in hepatocellular carcinoma. Contemp Oncol (Pozn) 2023;27(3):163-175.
    doi: 10.5114/wo.2023.133507pubmed: 38239867google scholar: lookup
  26. Zhou BW, Wu QQ, Mauki DH, Wang X, Zhang SR, Yin TT, Chen FL, Li C, Liu YH, Wang GD, Zhang YP. Germline gene fusions across species reveal the chromosomal instability regions and cancer susceptibility. iScience 2023 Dec 15;26(12):108431.
    doi: 10.1016/j.isci.2023.108431pubmed: 38205119google scholar: lookup
  27. Pimenta J, Prada J, Pires I, Cotovio M. Programmed Cell Death-Ligand 1 (PD-L1) Immunohistochemical Expression in Equine Melanocytic Tumors. Animals (Basel) 2023 Dec 22;14(1).
    doi: 10.3390/ani14010048pubmed: 38200779google scholar: lookup
  28. Zhang W, Xiao Y, Zhou Q, Zhu X, Zhang Y, Xiang Q, Wu S, Song X, Zhao J, Yuan R, Xiao B, Li L. KNSTRN Is a Prognostic Biomarker That Is Correlated with Immune Infiltration in Breast Cancer and Promotes Cell Cycle and Proliferation. Biochem Genet 2024 Oct;62(5):3709-3739.
    doi: 10.1007/s10528-023-10615-2pubmed: 38198023google scholar: lookup
  29. Wicks MN, Glinka M, Hill B, Houghton D, Sharghi M, Ferreira I, Adams D, Din S, Papatheodorou I, Kirkwood K, Cheeseman M, Burger A, Baldock RA, Arends MJ. The Comparative Pathology Workbench: Interactive visual analytics for biomedical data. J Pathol Inform 2023;14:100328.
    doi: 10.1016/j.jpi.2023.100328pubmed: 37693862google scholar: lookup
  30. Pimenta J, Pires I, Prada J, Cotovio M. E-Cadherin Immunostaining in Equine Melanocytic Tumors. Animals (Basel) 2023 Jul 6;13(13).
    doi: 10.3390/ani13132216pubmed: 37444014google scholar: lookup
  31. Rodrigues L, Watson J, Feng Y, Lewis B, Harvey G, Post G, Megquier K, White ME, Lambert L, Miller A, Lopes C, Zhao S. Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics. Sci Rep 2023 Jul 6;13(1):10935.
    doi: 10.1038/s41598-023-37505-2pubmed: 37414794google scholar: lookup
  32. Gniadecki R, O'Keefe S, Hennessey D, Iyer A. Is Cutaneous T-Cell Lymphoma Caused by Ultraviolet Radiation? A Comparison of UV Mutational Signatures in Malignant Melanoma and Mycosis Fungoides. Cells 2023 Jun 13;12(12).
    doi: 10.3390/cells12121616pubmed: 37371087google scholar: lookup
  33. Koo K, Wuenschmann A, Rendahl A, Song KY, Forster C, Wolf-Ringwall A, Borgatti A, Giubellino A. Expression and Prognostic Evaluation of the Receptor Tyrosine Kinase MET in Canine Malignant Melanoma. Vet Sci 2023 Mar 26;10(4).
    doi: 10.3390/vetsci10040249pubmed: 37104404google scholar: lookup
  34. AbdulJabbar K, Castillo SP, Hughes K, Davidson H, Boddy AM, Abegglen LM, Minoli L, Iussich S, Murchison EP, Graham TA, Spiro S, Maley CC, Aresu L, Palmieri C, Yuan Y. Bridging clinic and wildlife care with AI-powered pan-species computational pathology. Nat Commun 2023 Apr 26;14(1):2408.
    doi: 10.1038/s41467-023-37879-xpubmed: 37100774google scholar: lookup
  35. Oh JH, Cho JY. Comparative oncology: overcoming human cancer through companion animal studies. Exp Mol Med 2023 Apr;55(4):725-734.
    doi: 10.1038/s12276-023-00977-3pubmed: 37009802google scholar: lookup
  36. Feng Y, Hess PR, Tompkins SM, Hildebrand WH, Zhao S. A Kmer-based paired-end read de novo assembler and genotyper for canine MHC class I genotyping. iScience 2023 Feb 17;26(2):105996.
    doi: 10.1016/j.isci.2023.105996pubmed: 36798440google scholar: lookup
  37. Forsberg EMV, Riise R, Saellström S, Karlsson J, Alsén S, Bucher V, Hemminki AE, Olofsson Bagge R, Ny L, Nilsson LM, Rönnberg H, Nilsson JA. Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. Cancers (Basel) 2023 Jan 20;15(3).
    doi: 10.3390/cancers15030648pubmed: 36765608google scholar: lookup
  38. Stevenson VB, Klahn S, LeRoith T, Huckle WR. Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies. Front Vet Sci 2022;9:1046636.
    doi: 10.3389/fvets.2022.1046636pubmed: 36686160google scholar: lookup
  39. Pimenta J, Prada J, Cotovio M. Equine Melanocytic Tumors: A Narrative Review. Animals (Basel) 2023 Jan 10;13(2).
    doi: 10.3390/ani13020247pubmed: 36670786google scholar: lookup
  40. Hernández-Verdin I, Akdemir KC, Ramazzotti D, Caravagna G, Labreche K, Mokhtari K, Hoang-Xuan K, Peyre M, Bielle F, Touat M, Idbaih A, Duval A, Sanson M, Alentorn A. Pan-cancer landscape of AID-related mutations, composite mutations, and their potential role in the ICI response. NPJ Precis Oncol 2022 Dec 1;6(1):89.
    doi: 10.1038/s41698-022-00331-2pubmed: 36456685google scholar: lookup
  41. Yi Z, Gao Y, Yu F, Zhu Y, Liu H, Li J, Murua Escobar H. Interventions for treatment of cutaneous melanoma in horses: a structured literature review. Vet Res Commun 2023 Jun;47(2):347-360.
    doi: 10.1007/s11259-022-10023-8pubmed: 36329228google scholar: lookup
  42. Gao Y, Jiang G, Yang W, Jin W, Gong J, Xu X, Niu X. Animal-SNPAtlas: a comprehensive SNP database for multiple animals. Nucleic Acids Res 2023 Jan 6;51(D1):D816-D826.
    doi: 10.1093/nar/gkac954pubmed: 36300636google scholar: lookup
  43. Pinard CJ, Lagree A, Lu FI, Klein J, Oblak ML, Salgado R, Cardenas JCP, Brunetti B, Muscatello LV, Sarli G, Foschini MP, Hardas A, Castillo SP, AbdulJabbar K, Yuan Y, Moore DA, Tran WT. Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy. Cancers (Basel) 2022 Oct 13;14(20).
    doi: 10.3390/cancers14205008pubmed: 36291791google scholar: lookup
  44. Birkeälv S, Harland M, Matsuyama LSAS, Rashid M, Mehta I, Laye JP, Haase K, Mell T, Iyer V, Robles-Espinoza CD, McDermott U, van Loo P, Kuijjer ML, Possik PA, Maria Engler SS, Bishop DT, Newton-Bishop J, Adams DJ. Mutually exclusive genetic interactions and gene essentiality shape the genomic landscape of primary melanoma. J Pathol 2023 Jan;259(1):56-68.
    doi: 10.1002/path.6019pubmed: 36219477google scholar: lookup
  45. Yu Y, Manders F, Grinwis GCM, Groenen MAM, Crooijmans RPMA. A recurrent somatic missense mutation in GNAS gene identified in familial thyroid follicular cell carcinomas in German longhaired pointer dogs. BMC Genomics 2022 Sep 23;23(1):669.
    doi: 10.1186/s12864-022-08885-ypubmed: 36151521google scholar: lookup
  46. Giannuzzi D, Marconato L, Fanelli A, Licenziato L, De Maria R, Rinaldi A, Rotta L, Rouquet N, Birolo G, Fariselli P, Mensah AA, Bertoni F, Aresu L. The genomic landscape of canine diffuse large B-cell lymphoma identifies distinct subtypes with clinical and therapeutic implications. Lab Anim (NY) 2022 Jul;51(7):191-202.
    doi: 10.1038/s41684-022-00998-xpubmed: 35726023google scholar: lookup
  47. Wang M, Banik I, Shain AH, Yeh I, Bastian BC. Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes. Genome Med 2022 Jun 16;14(1):65.
    doi: 10.1186/s13073-022-01068-0pubmed: 35706047google scholar: lookup
  48. Riccardo F, Tarone L, Camerino M, Giacobino D, Iussich S, Barutello G, Arigoni M, Conti L, Bolli E, Quaglino E, Merighi IF, Morello E, Dentini A, Ferrone S, Buracco P, Cavallo F. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. J Immunother Cancer 2022 May;10(5).
    doi: 10.1136/jitc-2021-004007pubmed: 35580930google scholar: lookup
  49. Amudzi AA, Piedra-Mora C, Ma DJ, Wong NB, David CN, Robinson NA, Almela RM, Richmond JM. Using Gene Expression Analysis to Understand Complex Autoimmune Skin Disease Patients: A Series of Four Canine Cutaneous Lupus Erythematosus Cases. Front Vet Sci 2022;9:778934.
    doi: 10.3389/fvets.2022.778934pubmed: 35280134google scholar: lookup
  50. Tarone L, Giacobino D, Camerino M, Ferrone S, Buracco P, Cavallo F, Riccardo F. Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research. Front Vet Sci 2022;9:803093.
    doi: 10.3389/fvets.2022.803093pubmed: 35224082google scholar: lookup
  51. Conrad D, Kehl A, Beitzinger C, Metzler T, Steiger K, Pfarr N, Fischer K, Klopfleisch R, Aupperle-Lellbach H. Molecular Genetic Investigation of Digital Melanoma in Dogs. Vet Sci 2022 Jan 30;9(2).
    doi: 10.3390/vetsci9020056pubmed: 35202309google scholar: lookup
  52. Du L, Wang D, Wei X, Liu C, Xiao Z, Qian W, Song Y, Hou X. MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis. BMC Gastroenterol 2022 Jan 21;22(1):29.
    doi: 10.1186/s12876-022-02101-7pubmed: 35062876google scholar: lookup
  53. Prouteau A, Mottier S, Primot A, Cadieu E, Bachelot L, Botherel N, Cabillic F, Houel A, Cornevin L, Kergal C, Corre S, Abadie J, Hitte C, Gilot D, Lindblad-Toh K, André C, Derrien T, Hedan B. Canine Oral Melanoma Genomic and Transcriptomic Study Defines Two Molecular Subgroups with Different Therapeutical Targets. Cancers (Basel) 2022 Jan 6;14(2).
    doi: 10.3390/cancers14020276pubmed: 35053440google scholar: lookup
  54. Sparger EE, Chang H, Chin N, Rebhun RB, Withers SS, Kieu H, Canter RJ, Monjazeb AM, Kent MS. T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma. Front Vet Sci 2021;8:772932.
    doi: 10.3389/fvets.2021.772932pubmed: 34926643google scholar: lookup
  55. Von Rueden SK, Fan TM. Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. Front Oncol 2021;11:773420.
    doi: 10.3389/fonc.2021.773420pubmed: 34869014google scholar: lookup
  56. Hardwick L. A Comparative View on Molecular Alterations and Potential Therapeutic Strategies for Canine Oral Melanoma. Vet Sci 2021 Nov 22;8(11).
    doi: 10.3390/vetsci8110286pubmed: 34822659google scholar: lookup
  57. Scattone NV, Epiphanio TMF, Caddrobi KG, Ferrão JSP, Hernandez-Blazquez FJ, Loureiro APM, Massoco CO, Dagli MLZ. Quantification of Global DNA Methylation in Canine Melanotic and Amelanotic Oral Mucosal Melanomas and Peripheral Blood Leukocytes From the Same Patients With OMM: First Study. Front Vet Sci 2021;8:680181.
    doi: 10.3389/fvets.2021.680181pubmed: 34504885google scholar: lookup
  58. Fonseca-Alves CE, Ferreira Ê, de Oliveira Massoco C, Strauss BE, Fávaro WJ, Durán N, Oyafuso da Cruz N, Dos Santos Cunha SC, Castro JLC, Rangel MMM, Brunner CHM, Tellado M, Dos Anjos DS, Fernandes SC, Barbosa de Nardi A, Biondi LR, Dagli MLZ. Current Status of Canine Melanoma Diagnosis and Therapy: Report From a Colloquium on Canine Melanoma Organized by ABROVET (Brazilian Association of Veterinary Oncology). Front Vet Sci 2021;8:707025.
    doi: 10.3389/fvets.2021.707025pubmed: 34485435google scholar: lookup
  59. Grassinger JM, Floren A, Müller T, Cerezo-Echevarria A, Beitzinger C, Conrad D, Törner K, Staudacher M, Aupperle-Lellbach H. Digital Lesions in Dogs: A Statistical Breed Analysis of 2912 Cases. Vet Sci 2021 Jul 17;8(7).
    doi: 10.3390/vetsci8070136pubmed: 34357928google scholar: lookup
  60. Alsaihati BA, Ho KL, Watson J, Feng Y, Wang T, Dobbin KK, Zhao S. Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds. Nat Commun 2021 Aug 3;12(1):4670.
    doi: 10.1038/s41467-021-24836-9pubmed: 34344882google scholar: lookup
  61. Ferreira I, Droop A, Edwards O, Wong K, Harle V, Habeeb O, Gharpuray-Pandit D, Houghton J, Wiedemeyer K, Mentzel T, Billings SD, Ko JS, Füzesi L, Mulholland K, Prusac IK, Liegl-Atzwanger B, de Saint Aubain N, Caldwell H, Riva L, van der Weyden L, Arends MJ, Brenn T, Adams DJ. The clinicopathologic spectrum and genomic landscape of de-/trans-differentiated melanoma. Mod Pathol 2021 Nov;34(11):2009-2019.
    doi: 10.1038/s41379-021-00857-zpubmed: 34155350google scholar: lookup
  62. Deng P, Zhou R, Zhang J, Cao L. Increased Expression of KNSTRN in Lung Adenocarcinoma Predicts Poor Prognosis: A Bioinformatics Analysis Based on TCGA Data. J Cancer 2021;12(11):3239-3248.
    doi: 10.7150/jca.51591pubmed: 33976733google scholar: lookup
  63. Buchbinder EI, Weirather JL, Manos M, Quattrochi BJ, Sholl LM, Brennick RC, Bowling P, Bailey N, Magarace L, Ott PA, Haq R, Izar B, Giobbie-Hurder A, Hodi FS. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. Cancer Med 2021 Apr;10(8):2627-2635.
    doi: 10.1002/cam4.3789pubmed: 33724703google scholar: lookup
  64. Tobin SJ, Chang H, Kent MS, Davies AE. JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines. Vet Comp Oncol 2021 Sep;19(3):518-528.
    doi: 10.1111/vco.12691pubmed: 33715247google scholar: lookup
  65. Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, Deguchi T, Kato Y, Yamamoto S, Yamamoto K, Toda M, Nakajima C, Suzuki Y, Murata S, Ohashi K. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol 2021 Feb 12;5(1):10.
    doi: 10.1038/s41698-021-00147-6pubmed: 33580183google scholar: lookup
  66. Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Burd CE, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G. Melanoma models for the next generation of therapies. Cancer Cell 2021 May 10;39(5):610-631.
    doi: 10.1016/j.ccell.2021.01.011pubmed: 33545064google scholar: lookup
  67. Prouteau A, Denis JA, De Fornel P, Cadieu E, Derrien T, Kergal C, Botherel N, Ulvé R, Rault M, Bouzidi A, François R, Dorso L, Lespagnol A, Devauchelle P, Abadie J, André C, Hédan B. Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma. Sci Rep 2021 Jan 13;11(1):877.
    doi: 10.1038/s41598-020-80332-ypubmed: 33441840google scholar: lookup
  68. Bollard SM, Casalou C, Goh CY, Tobin DJ, Kelly P, McCann A, Potter SM. Circulating Melanoma-Derived Extracellular Vesicles: Impact on Melanoma Diagnosis, Progression Monitoring, and Treatment Response. Pharmaceuticals (Basel) 2020 Dec 18;13(12).
    doi: 10.3390/ph13120475pubmed: 33353043google scholar: lookup
  69. Brocca G, Poncina B, Sammarco A, Cavicchioli L, Castagnaro M. KIT Somatic Mutations and Immunohistochemical Expression in Canine Oral Melanoma. Animals (Basel) 2020 Dec 10;10(12).
    doi: 10.3390/ani10122370pubmed: 33321993google scholar: lookup
  70. Assenmacher CA, Santagostino SF, Oyama MA, Marine JC, Bonvin E, Radaelli E. Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis. J Histochem Cytochem 2021 Mar;69(3):203-218.
    doi: 10.1369/0022155420977970pubmed: 33283624google scholar: lookup
  71. Sun P, Li Y, Chao X, Li J, Luo R, Li M, He J. Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey. BMC Cancer 2020 Oct 14;20(1):994.
    doi: 10.1186/s12885-020-07481-1pubmed: 33054725google scholar: lookup
  72. Wei BR, Hoover SB, Peer CJ, Dwyer JE, Adissu HA, Shankarappa P, Yang H, Lee M, Peat TJ, Figg WD, Simpson RM. Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma. Mol Cancer Ther 2020 Nov;19(11):2308-2318.
    doi: 10.1158/1535-7163.MCT-19-0858pubmed: 32943547google scholar: lookup
  73. LeBlanc AK, Mazcko CN. Improving human cancer therapy through the evaluation of pet dogs. Nat Rev Cancer 2020 Dec;20(12):727-742.
    doi: 10.1038/s41568-020-0297-3pubmed: 32934365google scholar: lookup
  74. van der Weyden L, Brenn T, Patton EE, Wood GA, Adams DJ. Spontaneously occurring melanoma in animals and their relevance to human melanoma. J Pathol 2020 Sep;252(1):4-21.
    doi: 10.1002/path.5505pubmed: 32652526google scholar: lookup
  75. Feng J, Li C, Xu R, Li Y, Hou Q, Feng R, Wang S, Zhang L, Li C. DpdtC-Induced EMT Inhibition in MGC-803 Cells Was Partly through Ferritinophagy-Mediated ROS/p53 Pathway. Oxid Med Cell Longev 2020;2020:9762390.
    doi: 10.1155/2020/9762390pubmed: 32256964google scholar: lookup
  76. Amin SB, Anderson KJ, Boudreau CE, Martinez-Ledesma E, Kocakavuk E, Johnson KC, Barthel FP, Varn FS, Kassab C, Ling X, Kim H, Barter M, Lau CC, Ngan CY, Chapman M, Koehler JW, Long JP, Miller AD, Miller CR, Porter BF, Rissi DR, Mazcko C, LeBlanc AK, Dickinson PJ, Packer RA, Taylor AR, Rossmeisl JH Jr, Woolard KD, Heimberger AB, Levine JM, Verhaak RGW. Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell 2020 Feb 10;37(2):243-257.e7.
    doi: 10.1016/j.ccell.2020.01.004pubmed: 32049048google scholar: lookup
  77. Brocca G, Ferraresso S, Zamboni C, Martinez-Merlo EM, Ferro S, Goldschmidt MH, Castagnaro M. Array Comparative Genomic Hybridization Analysis Reveals Significantly Enriched Pathways in Canine Oral Melanoma. Front Oncol 2019;9:1397.
    doi: 10.3389/fonc.2019.01397pubmed: 31921654google scholar: lookup
  78. Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Semin Cancer Biol 2020 Apr;61:139-148.
    doi: 10.1016/j.semcancer.2019.09.013pubmed: 31655118google scholar: lookup
  79. Somarelli JA, Gardner H, Cannataro VL, Gunady EF, Boddy AM, Johnson NA, Fisk JN, Gaffney SG, Chuang JH, Li S, Ciccarelli FD, Panchenko AR, Megquier K, Kumar S, Dornburg A, DeGregori J, Townsend JP. Molecular Biology and Evolution of Cancer: From Discovery to Action. Mol Biol Evol 2020 Feb 1;37(2):320-326.
    doi: 10.1093/molbev/msz242pubmed: 31642480google scholar: lookup
  80. Colombino M, Paliogiannis P, Cossu A, De Re V, Miolo G, Botti G, Scognamiglio G, Ascierto PA, Santeufemia DA, Fraggetta F, Manca A, Sini MC, Casula M, Palomba G, Pisano M, Doneddu V, Lissia A, Fedeli MA, Palmieri G. BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. J Clin Med 2019 Oct 1;8(10).
    doi: 10.3390/jcm8101577pubmed: 31581559google scholar: lookup
  81. Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun 2019 Jul 18;10(1):3163.
    doi: 10.1038/s41467-019-11107-xpubmed: 31320640google scholar: lookup
  82. Prouteau A, André C. Canine Melanomas as Models for Human Melanomas: Clinical, Histological, and Genetic Comparison. Genes (Basel) 2019 Jun 30;10(7).
    doi: 10.3390/genes10070501pubmed: 31262050google scholar: lookup
  83. Hitte C, Le Béguec C, Cadieu E, Wucher V, Primot A, Prouteau A, Botherel N, Hédan B, Lindblad-Toh K, André C, Derrien T. Genome-Wide Analysis of Long Non-Coding RNA Profiles in Canine Oral Melanomas. Genes (Basel) 2019 Jun 23;10(6).
    doi: 10.3390/genes10060477pubmed: 31234577google scholar: lookup
  84. Li Y, Zhang MC, Xu XK, Zhao Y, Mahanand C, Zhu T, Deng H, Nevo E, Du JZ, Chen XQ. Functional Diversity of p53 in Human and Wild Animals. Front Endocrinol (Lausanne) 2019;10:152.
    doi: 10.3389/fendo.2019.00152pubmed: 30915036google scholar: lookup
Subscribe to our newsletter
Join 99,658 horse owners like you who receive our email updates on horse health and nutrition.